BALTIMORE, Nov. 13, 2018 /PRNewswire/ -- Trialworks LLC, the leading litigation software company and owner of the Needles and Trialworks platforms, announced today the addition of David Wagner IV as the group's new Chief Operating Officer (COO) and Head of the Needles brand.
Wagner joins Needles from Omnitracs, a Vista Equity Partners portfolio company with over 1,000 employees supporting 12,000 customers in more than 70 countries. During his tenure he led operations, support, inside sales and strategic programs as Vice President. He is also a graduate of Vista's prestigious High Potential Leadership Program. Wagner began his career at medical start up Civatech before moving to KPMG, where he advised leading technology companies on strategy and operations.
Wagner's new role marks a larger move in the company's anticipated 2019 growth strategy. Leading business operations, Wagner will be responsible for technology innovation, research, marketing, sales, and customer support.
Wagner joins the company in the midst of a robust software development phase. With major company news set to be announced next quarter, Wagner will lead the rollout of Needles' new product offerings and oversee Needles' continued best-in-class customer support.
Ryan Pakter, Managing Director of Trialworks, said: "We continue to invest heavily in our senior team and the addition of David is emblematic of that investment and our ability to attract top talent." Pakter added, "David's experience was critical in accelerating Omnitracs' growth and technology development, and we are excited for him to bring his skillset to Needles to help streamline our operations and processes, thereby better positioning us for high growth."
Wagner is the latest key addition to the company's senior leadership team, which has been bolstered significantly. Wagner will work closely with other recent additions to the senior team, including Don O'Leary, the group's Chief Financial Officer, who joined from Nike Canada, and Giorgio Garrido, the Head of Business Development and Marketplace, who comes to Needles from S3 Ventures.
The expansion of Needles' executive team comes during a period of rapid growth and development. The company is investing more aggressively than at any point in its history, multiplying its in-house engineering team and bringing on Yossi Shemesh (Oliver, Mobli) to lead the team's development of a web-based version of Needles' software.
"When Ridge Road's principals acquired Trialworks and Needles, we were committed to reinvesting heavily in the business to expand our software offering for both platforms and to adding top talent as we continue to grow the business for the long-term. We look forward to announcing several major product developments for Needles in coming weeks, including updates to the recently-released Needles 5, and Needles Cloud, which will be released in 2019. This is an exciting time for our company," said Michael Mager, co-Chairman of Trialworks LLC.
About Trialworks LLC and Needles Trialworks LLC is the holding company that owns Trialworks and Needles, two of the most successful and trusted brands in the legal software industry. Ridge Road principals Adam Jiwan and Michael Mager made a substantial majority control investment in the businesses in 2017. These two companies have a combined 55 years of operating history and over 2,500 law firm clients. Together, Trialworks and Needles are the leaders in providing case management software for plaintiff-focused law firms, with a network of more than 40,000 active users.
About Ridge Road Capital Partners Ridge Road is an owner-operated investment holding company. Ridge Road employs a permanent capital base to acquire founder-led businesses with proven business models and capacity for growth. Since its establishment in late 2012, the group has taken control positions in multiple businesses globally, completing 10 transactions.